Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

iOpeners

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Alcon showcases new data at APACRS 2025, emphasizing advancements in IOL technology and surgical precision for improved patient outcomes.

Alcon presenting at APACRS 2025

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

European Commission approves aflibercept biosimilar Mynzepli

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%. 

Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

1rem

Thanks for your interest in this podcast. Please read this important program information before listening.

Glaucoma is a leading cause of irreversible blindness and affects approximately 80 million people globally, with projections to exceed 111 million by 2040. We know that the elevated intraocular pressure is the key modifiable risk factor which is why reducing intraocular pressure is central to treatment strategies.

In this podcast, expert faculty from the featured symposium at the 2025 EnVision Summit share insights about interventional glaucoma co-management.

 from Moran Eye Center in Salt Lake City, UT; 

 from Connecticut Eye Physicians in New Haven, CT; 

 from the Cleveland Clinic’s Cole Eye Institute in Cleveland, Ohio; and optometrist Jessica Steen from the Nova Southeastern University College of Optometry in Fort Lauderdale, FL.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Alcon and Sun Pharmaceutical Industries, Inc.

Glaucoma Specialist
Residency Program Director
Vice Chair of Education
Moran Eye Center
Salt Lake City, UT

 AbbVie, Elios Vision, Glaukos, Nova Eye Medical; 

Consulting Surgeon
Scarsdale Ophthalmology Associates
Keyhani Eye Associates
Jefferson Valley, NY
Connecticut Eye Physicians
New York and Connecticut
New Haven, CT

; MST, Nextech, Nova Eye Medical, Sight Sciences: 

: Bausch + Lomb, Glaukos, MST, Nova Eye Medical, Sight Sciences, RxSight; 

Associate Program Director
Cole Eye Institute
Cleveland Clinic
Cleveland, OH

Associate Professor
Director, Glaucoma Service
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

: Alcon, Allergan, Astellas Pharma, Bausch + Lomb, Carl Zeiss Meditec, Viatris; 

: Alcon, Allergan, Astellas Pharma, Bausch + Lomb, Carl Zeiss Meditec, Eyenovia, Glaukos, iCare, Ocuphire Pharma, OcuTerra Therapeutics, Opus Genetics, Peripherex, RadiusXR, Santen Pharmaceutical, Viatris; 

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

3 Things You Should Know About Interventional Glaucoma Comanagement

Recently approved anti-VEGF agents that target additional pathways and offer innovative delivery methods with longer-lasting effects may provide advantages over older anti-VEGF agents in managing patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In this podcast, expert faculty discuss the roles of ophthalmologists and optometrists in managing nAMD and DME in an evolving treatment landscape, from screening and diagnosis to referral and ongoing patient care.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Frederick M. Leader Professor of Ophthalmology
Associate Professor of Ophthalmology, Retina Division
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, MD

: Apellis, EyePoint, Genentech/Roche, Iveric Bio, Regeneron; 

Assistant Professor
Department of Ophthalmology and Vision Sciences
University of Illinois College of Medicine
Chicago, IL

Justine Cheng, MD, has no relevant financial relationships with ineligible companies.

Assistant Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL

 AbbVie, Alcon, Alimera Sciences/ANI Pharmaceuticals, Genentech.

Professor of Optometry
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

 American Diabetes Association, Genentech, Regeneron, Vision Service Plan (VSP).

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Thyroid eye disease (TED), a rare autoimmune condition, can be sight-threatening, debilitating, and disfiguring, severely impacting patients’ quality of life and daily functioning. Traditional management approaches for TED have centered on immunomodulatory therapy and surgical interventions. In January 2020, the US Food and Drug Administration (FDA) approved teprotumumab, the first therapy specifically indicated for TED. As treatment options evolve, there is an increasing need for a patient-centered, multidisciplinary approach, which is essential to address individual patient needs throughout the disease course.

 podcast provides an in-depth review of some of the key highlights from a satellite symposium that took place at the Envision Summit 2025 meeting in February 2025.This unique and engaging activity focuses on the practical aspects of managing patients with thyroid eye disease, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

This activity is supported by an educational grant from Amgen, Inc.

Professor of Clinical Ophthalmology
Oculofacial Plastic and Reconstructive Surgery
Orbital Surgery and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

 Amgen, Argenx, Horizon Therapeutics, Immunovant, Tourmaline Bio; 

Assistant Professor
Department of Ophthalmology
University of Colorado School of Medicine
Anschutz Medical Campus
Denver, CO

 Alcon, Aldeyra Therapeutics, Allergan/AbbVie, Avellino, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder, Claris Bio, Dompé, Eyevance/Santen Pharmaceutical, Glaukos, KALA BIO, Myze, Orasis Pharmaceuticals, Oyster Point Pharma/Viatris, RVL Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Thea, Topcon, Twenty/Twenty Therapeutics, Verséa, Visus Therapeutics

Robert H. Bell Endowed Chair in Ophthalmology
Associate Chief Medical Officer of Ambulatory Services
UCHealth University of Colorado Hospital
Associate Professor, Division of Oculofacial Plastic and Reconstructive Surgery
Department of Ophthalmology
University of Colorado School of Medicine
Aurora, CO

Dr Liao has no relevant financial relationships with ineligible companies to disclose.

CEO/Owner
Jennifer Murdock, MD, PLLC
Miami, FL

3 Things You Should Know About Early Treatment Intervention for TED

Geographic atrophy, an advanced stage of age-related macular degeneration, is a significant cause of vision loss. Given the progressive nature of geographic atrophy and its significant impact on quality of life, educating health care professionals about the disease burden, diagnostic strategies, and evolving management strategies is essential.

 podcast provides an in-depth review of some of the key highlights from the Envision Summit 2025 meeting, held in February 2025. This unique and engaging activity focuses on the practical aspects of managing patients with geographic atrophy, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

This activity is supported by educational grants from Astellas Pharma US, Apellis Pharmaceuticals, Carl Zeiss Meditec.

Assistant Professor of Ophthalmology and Visual Science
Assistant Professor of Pathology
UChicago Medicine
Chicago, IL

Xiao Yi (Ellie) Zhou, MD, has no relevant financial relationships with ineligible companies to disclose.

3 Things You Should Know About the GA Pipeline 

The lacrimal functional unit, which includes the lacrimal glands and meibomian glands, can be stimulated via the trigeminal nerve to trigger production of the tear film. This approach can be used to manage dry eye disease (DED) in patients undergoing corneal refractive surgery. In this podcast, an expert explores opportunities to use this approach to treat patients with DED.

This activity is supported by educational grants from Viatris, Inc, and Nordic Pharma, Inc.

Associate Professor of Ophthalmology
Cornea Fellowship Director
Willis Eye Hospital
Philadelphia, PA

 BioTissue, Bruder, Glaukos, Recordati Rare Diseases; 

 BioTissue, Recordati Rare Diseases, Tarsus; 

The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

The 14th annual Glaucoma 360 conference will take place February 6 to 8, 2025, at the Westin St. Francis on Union Square in San Francisco, California. Co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, the three-day event highlights progress in glaucoma care while fostering innovation and collaboration.

The conference opens on Thursday, February 6, with a gala to celebrate advancements in the field, followed by the New Horizons Forum on Friday, February 7, which serves as an incubator for innovation. Topics include artificial intelligence in glaucoma management, neuroprotection and vision restoration, and cross-species insights from veterinary ophthalmology. Carla J. Siegfried, MD, president of the American Glaucoma Society, will deliver the keynote address.

The program on Saturday, February 8, begins with a continuing medical education program featuring M. Roy Wilson, MD, MS, who will present the Shaffer-Hetherington-Hoskins Lecture, and concludes with an optometric symposium. Visit 

SAP Partner

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias. 

Green outlines the status of the research, involving a unique combination of transforming growth factor beta-3 and dexamethasone, and the setup for a proof-of-concept study (via TheiaNova, a spin-out early-stage company of the University of Auckland). 

Green also offers career advice for vision scientists and entrepreneurs, advising that making the transition from basic research to research translation is challenging and that having an application in mind is crucial. He emphasizes the importance of persevering through the highs and lows of research and development, highlighting the long-term benefits and sense of achievement.

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias. 

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

In this PER On Air Ophthalmology Times podcast, an expert panel discusses the latest advances in X-linked retinitis pigmentosa and how to optimize diagnosis as well as developments in gene therapy. 

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Thyroid eye disease is a condition frequently associated with Graves disease that involves both acute and chronic inflammation of the orbit. Patients may experience ocular discomfort, appearance changes, and vision loss. In this podcast, an expert panel discusses diagnosing TED and providing appropriate pharmacologic and surgical treatments. 

In this PER On Air Ophthalmology Times podcast, an expert panel discusses diagnosing TED and providing appropriate pharmacologic and surgical treatments. 

Advancing the optimal diagnosis & treatment of thyroid eye disease

 podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK.

Clinical Assistant Professor of Ophthalmology

Vice President, Board of Trustees of Virginia Optometric

Secretary/Treasurer, Richmond Optometric Society

Assistant Professor, Uniformed Services University, School of Medicine, Physical Medicine and Rehabilitation Department

Assistant Professor of Clinical Ophthalmology

Pediatric and Adult Cornea, Cataract, and External Diseases

Director of Ophthalmology Medical Student Education

Bascom Palmer Eye Institute, University of Miami Miller School of Medicine

In this PER On Air Ophthalmology Times podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK. 

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect NEI’s independence and ensure vision research funding.

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

From firsts to the future: A pioneer's perspective on ophthalmology

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

Hidden signs of systemic disease, including heart attacks, may first reveal themselves through visual symptoms or subtle patient cues in the exam chair.

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

Current applications and future outlook on integrating robotic technology in the operating room.

Robotic precision: Elevating the state of laser cataract surgery 

EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning

Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care.

To learn more about or to register for EyeCon 2025, 

Here’s one way to carry the summertime vibe into the fall: The 2025 

 EyeCon® conference is set for September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida. Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas, is a member of this year’s EyeCon educational committee, which also includes Joseph Allen, OD, FAAO, Dipl ABO; Sruthi Arepalli, MD; and Jade Coats, OD, FAAO. Together, they’ve crafted a program designed to foster dynamic, cross-disciplinary discussion between ophthalmologists and optometrists. 

This year’s agenda covers a wide range of topics, offering key insights into the latest diagnostic strategies and clinical trial data across specialties. Additionally, this year’s format represents a shift from past meetings, with the introduction of an educational committee, rather than individual chairs, overseeing the structure and direction of sessions.

Smith, who will help lead a glaucoma session, recently sat down with the 

 to share a sample of what attendees can expect. She noted that it has been just over a decade since the first minimally invasive glaucoma surgery (MIGS) procedures, such as the iStent, were introduced around 2012, marking an important milestone in the field. She added, “We’ve come full circle, sort of learning all the different MIGS procedures that have come out, and then we’re at the place now where we’re trying to look at each procedure and its long-term effects in reducing IOP and preserving vision.”

The session will highlight phase 3 clinical trials that demonstrate the benefits of MIGS and explore broader shifts in glaucoma management. One key example is the LiGHT trial, which provided evidence for early intervention strategies.

Smith emphasized the importance of both timely care and communication between specialists across a patient’s care journey. “Glaucoma patients have disease for the long term. They sometimes see different specialists over their lifetime. One of the things I always say works well for any patient that has a chronic disease is communication, making sure we get records or we exchange records as new things occur.”

Looking ahead, Smith sees the field moving toward earlier, less-invasive treatment options and greater collaboration in co-management. “There is a big burden of glaucoma. We are well aware of that, and that over time that burden will only increase. With that going on then the burden to take care of these patients is there, and for us to do a better job taking care of patients and not referring them later on in their disease, but early on when we can push back some of the more invasive interventions that we have available like trabeculectomies and tube shunts.”

The EyeCon meeting will feature what Smith calls structured “program pods” to foster focused discussion, as well as a collaborative environment where ophthalmologists and optometrists can address shared challenges in patient care. The exhibit hall will also provide opportunities to engage with industry partners and learn about new technologies.

Smith noted that the venue itself encourages balance: “Fun location. You can bring your family along with you. You spend portions of the day learning, and then you’re able to spend time doing things that are more social in that environment, spending time on the beach.”

Most importantly, she stressed that the educational committee’s goal is for attendees to leave with practical insights they can implement immediately. “One thing we always like to say as the educational committee is to make sure we provide substance that allows people to go home and come Monday morning when they show up at their offices, there are certain things they’ve learned at the meeting that they can use on day 1.”

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.

Clinical Diagnosis

Latest News